指南与共识心脑血管急症重症综合管理与镇静镇痛

择期侵入性操作患者抗血小板治疗管理:法国围术期止血工作组(GIHP)与法国血栓与止血研究组(GFHT)联合法国麻醉与重症医学会(SFAR)的建议

Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR).
指南 / 共识 · Anaesth Crit Care Pain Med · 2018-01-05
一句话结论择期侵入性操作前若需停用抗血小板药,建议阿司匹林、氯吡格雷、替格瑞洛和普拉格雷末次服药分别提前3、5、5、7天停药,并按操作出血风险与血栓风险分层管理。

法国围术期止血工作组(GIHP)与法国血栓与止血研究组(GFHT)联合法国麻醉与重症医学会(SFAR)制定了择期侵入性操作患者抗血小板治疗管理的最新建议,经讨论投票验证,除一项外所有建议均被赋予高强度。管理基于抗血小板治疗适应证和操作类型:操作出血风险按能否在无抗血小板药、单药或双药抗血小板治疗下实施分为高、中、低三类。若需术前停药,建议阿司匹林、氯吡格雷、替格瑞洛和普拉格雷末次服药分别提前3、5、5、7天。停药相关血栓风险按各适应证评估,冠状动脉疾病双联治疗者高于心血管预防、卒中二级预防或下肢动脉疾病单药治疗者。建议还涉及血小板功能检测的潜在作用、区域麻醉(含中枢神经轴麻醉和外周神经阻滞)及冠状动脉手术的抗血小板管理。

要点

  • 操作出血风险按能否在无抗血小板药、单药或双药抗血小板治疗下实施分为高、中、低三类。
  • 若需术前停用抗血小板药,建议阿司匹林、氯吡格雷、替格瑞洛和普拉格雷末次服药分别提前3、5、5、7天。
  • 停药相关血栓风险按各抗血小板治疗适应证评估,冠状动脉疾病双联治疗者高于单药用于心血管预防、卒中二级预防或下肢动脉疾病者。
  • 建议涉及血小板功能检测的潜在作用、区域麻醉(含中枢神经轴麻醉和外周神经阻滞)及冠状动脉手术的抗血小板管理。
  • 建议由GIHP与GFHT联合SFAR制定,经讨论投票验证,除一项外所有建议均被赋予高强度。

适用人群与场景

  • 接受择期侵入性操作、正在使用抗血小板治疗的患者。

诊断标准与关键阈值

  • 操作出血风险按能否在无抗血小板药、单药或双药抗血小板治疗下实施分为高、中、低三类。

处置流程与药物剂量

  • 若需术前停用抗血小板药,建议阿司匹林、氯吡格雷、替格瑞洛和普拉格雷末次服药分别提前3、5、5、7天。
  • 停药相关血栓风险按各抗血小板治疗适应证评估,冠状动脉疾病双联治疗者高于单药用于心血管预防、卒中二级预防或下肢动脉疾病者。
  • 建议涉及区域麻醉(含中枢神经轴麻醉和外周神经阻滞)及冠状动脉手术的抗血小板管理。
  • 建议涉及血小板功能检测的潜在作用。

研究设计与关键结果

  • 建议由法国围术期止血工作组(GIHP)与法国血栓与止血研究组(GFHT)联合法国麻醉与重症医学会(SFAR)制定,经讨论投票验证,除一项外所有建议均被赋予高强度。

证据类型、等级与局限

  • 证据类型:指南/共识;建议经讨论投票验证,除一项外所有建议均被赋予高强度。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 择期侵入性操作前按操作出血风险(高、中、低)和抗血小板治疗适应证评估是否停药及停药时机;若需停药,阿司匹林、氯吡格雷、替格瑞洛和普拉格雷末次服药分别提前3、5、5、7天。

指南或共识出处

  • 法国围术期止血工作组(GIHP)与法国血栓与止血研究组(GFHT)联合法国麻醉与重症医学会(SFAR)的建议(Anaesth Crit Care Pain Med)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Haemostasis and Thrombosis (GFHT) in collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR) drafted up-to-date proposals for the management of antiplatelet therapy in patients undergoing elective invasive procedures. The proposals were discussed and validated by a vote; all proposals but one could be assigned with a high strength. The management of antiplatelet therapy is based on their indication and the procedure. The risk of bleeding related to the procedure can be divided into high, moderate and low categories depending on the possibility of performing the procedure in patients receiving antiplatelet agents (none, monotherapy and dual antiplatelet therapy respectively). If discontinuation of antiplatelet therapy is indicated before the procedure, a last intake of aspirin, clopidogrel, ticagrelor and prasugrel 3, 5, 5 and 7 days before surgery respectively is proposed. The thrombotic risk associated with discontinuation should be assessed according to each specific indication of antiplatelet therapy and is higher for patients receiving dual therapy for coronary artery disease (with further refinements based on a few well-accepted items) than for those receiving monotherapy for cardiovascular prevention, for secondary stroke prevention or for lower extremity arterial disease. These proposals also address the issue of the potential role of platelet functional tests and consider management of antiplatelet therapy for regional anaesthesia, including central neuraxial anaesthesia and peripheral nerve blocks, and for coronary artery surgery.

来源:Anaesth Crit Care Pain Med,查看原文。版权归原作者所有。

参考来源

  1. Godier A, Fontana P, Motte S, et al. Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). Anaesth Crit Care Pain Med. 2018. PMID: 29309950. doi:10.1016/j.accpm.2017.12.012

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。